Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Operating Leases (2019 - 2026)

Standard Biotools has reported Operating Leases over the past 7 years, most recently at $25.0 million for Q4 2025.

  • Quarterly Operating Leases fell 2.16% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Dec 2025, down 2.16% year-over-year, with the annual reading at $25.0 million for FY2025, 2.16% down from the prior year.
  • Operating Leases was $25.0 million for Q4 2025 at Standard Biotools, up from $22.0 million in the prior quarter.
  • Over five years, Operating Leases peaked at $40.4 million in Q1 2021 and troughed at $22.0 million in Q3 2025.
  • The 5-year median for Operating Leases is $31.7 million (2023), against an average of $32.0 million.
  • Year-over-year, Operating Leases increased 14.57% in 2021 and then dropped 21.9% in 2025.
  • A 5-year view of Operating Leases shows it stood at $37.5 million in 2021, then fell by 9.23% to $34.1 million in 2022, then decreased by 10.88% to $30.4 million in 2023, then decreased by 15.75% to $25.6 million in 2024, then fell by 2.16% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Operating Leases are $25.0 million (Q4 2025), $22.0 million (Q3 2025), and $23.2 million (Q2 2025).